Many factors such as age of the patient, risk of hypoglycaemia, comorbidities, presence of complications, risk of weight gain after insulin initiation, cost of treatment, and so on should be taken into account when tailoring combination therapy to individual patient needs. This evidence concerns the gene INS and Hypoglycemia.